Streetbeat News

TVGN

Tevogen Bio Holdings Inc.

Industry

Biotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Open

1.12

Mkt cap

205M

Volume

202K

High

1.18

P/E Ratio

3.34

52-wk high

6.25

Low

1.12

Div yield

N/A

52-wk low

0.26

Tevogen Bio's CSO's recent share sales were tax-related, not discretionary. The leadership retains full equity, showing confidence in the company's potential. Tevogen anticipates $1B in launch-year revenue for its lead oncology product and $10B-$14B over five years.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 5:59 pm

Several health care stocks experienced significant price movements during Friday's intraday session. Notable gainers included Catheter Precision (AMEX:VTAK) with a 142.8% increase, and Tevogen Bio Holdings (NASDAQ:TVGN) with a 49.28% rise. On the losing side, NKGen Biotech (NASDAQ:NKGN) fell by 31.9%, and Orgenesis (NASDAQ:ORGS) declined by 28.05%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 4:31 pm

In Friday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Catheter Precision (AMEX:VTAK) with a 151.9% increase, Akanda (NASDAQ:AKAN) up 71.13%, and Tenon Medical (NASDAQ:TNON) rising 39.06%. On the losing side, Orgenesis (NASDAQ:ORGS) fell 37.9%, Molecular Templates (NASDAQ:MTEM) dropped 30.11%, and NKGen Biotech (NASDAQ:NKGN) decreased by 29.02%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 12:09 pm

On Thursday, several health care stocks experienced significant intraday movements. Notable gainers included Tevogen Bio Holdings, Molecular Templates, and Kazia Therapeutics, while Biodexa Pharmaceuticals and 180 Life Sciences were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 4:31 pm

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced a revenue forecast of $1 billion in its launch year for its oncology pipeline, with a 5-year estimate of $10-14 billion. The stock surged 100.07% due to this announcement and positive trial data for its SARS-CoV-2 immunotherapy.

Portfolio Pulse from Vandana Singh

October 17, 2024 | 3:57 pm

Tevogen Bio shares increased following the company's revenue projections for its SARS-CoV-2 treatment in cancer patients and its focus on additional therapeutic areas and long-term innovation goals.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 2:04 pm

Tevogen Bio Oncology projects $1 billion in revenue for its launch year and $10-$14 billion over five years, driven by its treatment for SARS-CoV-2 in cancer patients. The company also plans to expand into additional therapeutic areas and has long-term innovation goals.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:34 pm

The article highlights significant intraday movements in healthcare stocks, with notable gainers including 180 Life Sciences, Korro Bio, and Universe Pharmaceuticals, and losers such as Novavax and Tevogen Bio Holdings.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

In Tuesday's after-market session, several health care stocks experienced significant price movements. Biodexa Pharmaceuticals saw a remarkable 119% increase, while Petros Pharma, Helius Medical Tech, Vaccinex, Aditxt, and Gain Therapeutics also posted gains. Conversely, NewGenIvf Group, HCW Biologics, Carmell, ABVC BioPharma, Tevogen Bio Holdings, and Lipella Pharmaceuticals experienced declines.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 8:30 pm

Tevogen Bio shares have resumed trading, which may indicate a resolution of previous issues or new developments within the company.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 4:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.